Same Indication

Insulin Glargine vs Nivolumab

Insulin Glargine vs Nivolumab: Overview

This comparison examines the pharmacological differences between Insulin Glargine and Nivolumab.

Mechanism of Action

Insulin Glargine: Long-acting insulin analogue that binds insulin receptors.

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Insulin Glargine — 12-24 hours; Nivolumab — 27 days.

Chemical Properties

Type: Insulin Glargine — Protein; Nivolumab — Antibody.